{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for amphotericin root_Display\ Name in Display Name (approximate match)
Status:
Other
Class:
MIXTURE
Status:
US Previously Marketed
Source:
ENJUVIA by DURAMED
(2004)
Source URL:
First approved in 2004
Source:
ENJUVIA by DURAMED
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
ANDA091355
(2022)
Source URL:
First approved in 2022
Source:
ANDA091355
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
NCT02569632: Phase 4 Interventional Completed Meningococcal Infections
(2015)
Source URL:
First approved in 2014
Source:
BLA125549
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
NCT02569632: Phase 4 Interventional Completed Meningococcal Infections
(2015)
Source URL:
First approved in 2014
Source:
BLA125549
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
ANDA086996
(2024)
Source URL:
First approved in 2011
Source:
ANDA090545
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/Over-the-CounterOTCDrugs/StatusofOTCRulemakings/ucm071835.htm laxative:stimulant laxative sennosides a and b
Source URL:
First approved in 1998
Source:
21 CFR 334
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
M006
(2009)
Source URL:
First approved in 1997
Source:
NDA021184
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
21 CFR 341
(2019)
Source URL:
First approved in 1973
Source:
ANDA083365
Source URL:
Class:
MIXTURE
Status:
Investigational
Source:
NCT03849651: Phase 2 Interventional Active, not recruiting Acute Lymphoblastic Leukemia (ALL)
(2019)
Source URL:
Class:
PROTEIN
